BIOMIRA INC. ANNOUNCES FILING OF FINAL PROSPECTUS FOR RIGHTS OFFERING.EDMONTON, ALBERTA--(BUSINESS WIRE)--May 1, 1995--Biomira Inc. today announced that it has filed a final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. in all the provinces of Canada and a registration statement, including a final prospectus, in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. for a rights offering to its common shareholders of 7,507,513 units, each unit consisting of a common share and a warrant to purchase an additional common share. Each holder of common shares of record at the close of business on May 12, 1995 is entitled to receive one right for every common share held. Three rights entitle the holder to subscribe for one unit at a price of $3.60 per unit. Each warrant entitles the holder to purchase one common share at a price of $5.75 per common share until December 5, 1996. If all rights are subscribed for under this offering the gross proceeds will be approximately C$27 million, not including any proceeds from the exercise of the warrants. Almiria Capital Corp., formerly a principal shareholder of Biomira, has agreed to purchase a maximum of C$18 million of units not purchased pursuant to the rights offering. The net proceeds Net Proceeds The amount received after all costs are deducted from the sale of a piece of property or security. Notes: In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions). of the rights offering are anticipated to be used to fund ongoing development of the Company's products including the cost of clinical trials and expenses associated with regulatory approvals relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the Company's products. Biomira is a biotechnology company developing an integrated line of products for the diagnosis and treatment of cancer. CONTACT: Jim Devaney VP Finance and CFO See Chief Financial Officer. 403/490-2806 REPEATS: New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of 212-575-8822 or 800-221-2462; Boston 617-330-5311 or |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion